Authors: Brady, F.; Luthra, S.K.; Brown, G.D.; Osman, S.; Aboagye, E.; Saleem, A.; Price, P.M.

Source: Current Pharmaceutical Design, Volume 7, Number 18, 1 December 2001 , pp. 1863-1892(30)

Publisher: Bentham Science Publishers

Abstract:

Positron Emission Tomography (PET) has the potential to improve efficacy of established and novel cancer therapies and to assist more rapid and rational progression of promising novel therapies into the clinic. This is due to PET's unrivalled sensitivity and ability to monitor the pharmacokinetics and pharmacodynamics of drugs and biochemicals radiolabelled with short -lived positron emitting radioisotopes. PET is a multidisciplinary science which employs chemists, biologists, mathematicial modellers, pharmacologists as well as clinicians. Clinical research questions in oncology determine the methodological challenges faced by these other disciplines. Within this context we focus on the developments of the radiolabelled compounds that have underpinned the clinical work in oncology for monitoring tumour and normal tissue pharmacokinetics, assessment of tumour response, cell proliferation, gene expression, hypoxia, multidrug resistance and status of receptors on tumours.

Keywords: Radiolabelled Tracers; Anticancer Drugs; Positron Emission Tomography pet; anti cancer therapy; anticancer angents; n dihmethylamino ethyl acridine carboxamide; temozolomide; f fdg; c thymidine; muti drug resistance mdr; hypoxia

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013396907

Publication date: 2001-12-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Brady, F. ;  Luthra, S.K. ;  Brown, G.D. ;  Osman, S. ;  Aboagye, E. ;  Saleem, A. ;  Price, P.M.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers